Antidepressant prevalence for youths: a multi-national comparison

被引:62
作者
Zito, Julie M.
Tobi, Hilde
de Jong-van den Berg, Lolkje T. W.
Fegert, Joerg M.
Safer, Daniel J.
Janhsen, Katrin
Hansen, Dorte Gilsa
Gardner, James F.
Glaeske, Gerd
机构
[1] Univ Maryland, Dept Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA
[2] Univ Groningen, Groningen, Netherlands
[3] Univ Ulm, Ulm, Germany
[4] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
[5] Univ Bremen, Bremen, Germany
[6] Univ So Denmark, Odense, Denmark
关键词
pharmacoepidemiology; children and adolescents; antidepressants;
D O I
10.1002/pds.1254
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective To compare antidepressant prevalence data in youths across three western European countries (Denmark, Germany, and the Netherlands) with US regional data in terms of age and gender and to show proportional subclass antidepressant (ATD) use. Method A population-based analysis of administrative claims data for the year 2000 was undertaken in 0 to 19-year-old enrollees who were part of the insured populations from four countries having a total of from 72,570 to 480,680 members. Results AID medication utilization in the US dataset (1.63%) exceeded that of three Western European countries (prevalence ranged from 0.11 to 0.54%) by at least 3-fold. There were major variations in the use of subclasses: tricyclic antidepressants (TCAs) predominated in Germany while selective serotonin reuptake inhibitors (SSRls) predominated in the US, Denmark and the Netherlands. Conclusions Cross-national variations should be further explored to understand the factors related to these differences and how prevalence differences relate to effectiveness and safety. Community-based cohorts should be followed to establish outcomes in the usual practice setting. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:793 / 798
页数:6
相关论文
共 24 条
[1]  
American College of Neuropsychopharmacology, 2004, PREL REP TASK FORC S
[2]   A comparison of the socioeconomic and health status characteristics of uninsured, State Children's Health Insurance Program-eligible children in the United States with those of other groups of insured children: Implications for policy [J].
Byck, GR .
PEDIATRICS, 2000, 106 (01) :14-21
[3]   Increase in non-evidence based use of antidepressants in children is cause for concern [J].
Clavenna, A ;
Bonati, M ;
Rossi, E ;
De Rosa, M .
BRITISH MEDICAL JOURNAL, 2004, 328 (7441) :711-712
[4]   Trends in the use of antidepressants in a national sample of commercially insured, pediatric patients, 1998 to 2002 [J].
Delate, T ;
Gelenberg, AJ ;
Simmons, VA ;
Motheral, BR .
PSYCHIATRIC SERVICES, 2004, 55 (04) :387-391
[5]  
Garland EJ, 2004, CAN MED ASSOC J, V170, P489
[6]  
GRAHAM P, 1999, CHILD PSYCHIAT DEV A
[7]  
Heyman I, 2002, CHILD ADOLESCENT PSY, P998
[8]   Increased psychotropic drug consumption by children in the Netherlands during 1995-2001 is caused by increased use of methylphenidate by boys [J].
Hugtenburg, JG ;
Heerdink, ER ;
Egberts, ACG .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (05) :377-379
[9]   Efficacy and safety of antidepressants for children and adolescents [J].
Jureidini, JN ;
Doecke, CJ ;
Mansfield, PR ;
Haby, MM ;
Menkes, DB ;
Tonkin, AL .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7444) :879-883
[10]   Trends in psychotropic medication costs for children and adolescents, 1997-2000 [J].
Martin, A ;
Leslie, D .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2003, 157 (10) :997-1004